Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

322 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TF, Bernd HW, Feller AC, Klapper W, Stuhlmann-Laeisz C, Hummel M, Stein H, Lenze D, Hartmann S, Hansmann ML, Möller P, Cogliatti S, Pfreundschuh M, Trümper L, Loeffler M, Glass B, Schmitz N, Ott G, Rosenwald A; DSHNHL16. Horn H, et al. Among authors: feller ac. Leukemia. 2015 Jul;29(7):1564-70. doi: 10.1038/leu.2015.43. Epub 2015 Feb 17. Leukemia. 2015. PMID: 25687653
TP53 mutation and survival in aggressive B cell lymphoma.
Zenz T, Kreuz M, Fuge M, Klapper W, Horn H, Staiger AM, Winter D, Helfrich H, Huellein J, Hansmann ML, Stein H, Feller A, Möller P, Schmitz N, Trümper L, Loeffler M, Siebert R, Rosenwald A, Ott G, Pfreundschuh M, Stilgenbauer S; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Zenz T, et al. Int J Cancer. 2017 Oct 1;141(7):1381-1388. doi: 10.1002/ijc.30838. Epub 2017 Jun 26. Int J Cancer. 2017. PMID: 28614910 Clinical Trial.
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.
Bernd HW, Ziepert M, Thorns C, Klapper W, Wacker HH, Hummel M, Stein H, Hansmann ML, Ott G, Rosenwald A, Müller-Hermelink HK, Barth TF, Möller P, Cogliatti SB, Pfreundschuh M, Schmitz N, Trümper L, Höller S, Löffler M, Feller AC; German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Bernd HW, et al. Among authors: feller ac. Haematologica. 2009 Nov;94(11):1569-80. doi: 10.3324/haematol.2009.008862. Haematologica. 2009. PMID: 19880780 Free PMC article.
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G; German High-Grade Non-Hodgkin Lymphoma Study Group. Horn H, et al. Among authors: feller ac. Blood. 2013 Mar 21;121(12):2253-63. doi: 10.1182/blood-2012-06-435842. Epub 2013 Jan 18. Blood. 2013. PMID: 23335369 Free article.
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G; German High-Grade Lymphoma Study Group. Staiger AM, et al. Among authors: feller ac. J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19. J Clin Oncol. 2017. PMID: 28525305 Clinical Trial.
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.
Paul U, Richter J, Stuhlmann-Laiesz C, Kreuz M, Nagel I, Horn H, Staiger AM, Aukema SM, Hummel M, Ott G, Spang R, Rosenwald A, Feller AC, Cogliatti S, Stein H, Hansmann ML, Moller P, Szczepanowski M, Burkhardt B, Pfreundschuh M, Schmitz N, Loeffler M, Trümper L, Siebert R, Klapper W. Paul U, et al. Among authors: feller ac. Leuk Lymphoma. 2018 May;59(5):1213-1221. doi: 10.1080/10428194.2017.1365851. Epub 2017 Aug 25. Leuk Lymphoma. 2018. PMID: 28838257
The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
Mellert K, Martin M, Lennerz JK, Lüdeke M, Staiger AM, Kreuz M, Löffler M, Schmitz N, Trümper L, Feller AC, Hartmann S, Hansmann ML, Klapper W, Stein H, Rosenwald A, Ott G, Ziepert M, Möller P. Mellert K, et al. Among authors: feller ac. Br J Haematol. 2019 Dec;187(5):627-637. doi: 10.1111/bjh.16147. Epub 2019 Aug 12. Br J Haematol. 2019. PMID: 31407320 Free PMC article. Clinical Trial.
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AC, Möller P, Hansmann ML, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, Spang R; Emed Demonstrator Project; German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Staiger AM, et al. Among authors: feller ac. Leukemia. 2020 Feb;34(2):543-552. doi: 10.1038/s41375-019-0573-y. Epub 2019 Sep 17. Leukemia. 2020. PMID: 31530861 Clinical Trial.
Pathway activation patterns in diffuse large B-cell lymphomas.
Bentink S, Wessendorf S, Schwaenen C, Rosolowski M, Klapper W, Rosenwald A, Ott G, Banham AH, Berger H, Feller AC, Hansmann ML, Hasenclever D, Hummel M, Lenze D, Möller P, Stuerzenhofecker B, Loeffler M, Truemper L, Stein H, Siebert R, Spang R; Molecular Mechanisms in Malignant Lymphomas Network Project of the. Bentink S, et al. Among authors: feller ac. Leukemia. 2008 Sep;22(9):1746-54. doi: 10.1038/leu.2008.166. Epub 2008 Jun 26. Leukemia. 2008. PMID: 18580954
322 results